GNR could deliver an immune checkpoint inhibitor (e.g., anti-programmed death-ligand 1 (PD-L1) antibody) to the highly immunogenic tumor, inducing the release of granzyme B to turn “On” the fluorescence of GNR for real-time imaging of immunotherapy response. This evidence concerns the gene GZMB and neoplasm.